메뉴 건너뛰기




Volumn 11, Issue 9, 2016, Pages 831-834

The utilization of spirocyclic scaffolds in novel drug discovery

Author keywords

Drug discovery; spirocycles; spirocyclic scaffolds; structure based drug design

Indexed keywords

ENZYME; ENZYME INHIBITOR; IBUTAMOREN; LEDIPASVIR; MOLECULAR SCAFFOLD; ROLAPITANT; TOFOGLIFLOZIN; UBROGEPANT; ZOLIFLODACIN; HETEROCYCLIC COMPOUND; SPIRO COMPOUND;

EID: 84973650162     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2016.1195367     Document Type: Editorial
Times cited : (210)

References (28)
  • 1
    • 84910274043 scopus 로고
    • The role of potassium in the natriuretic response to a steroidal lactone (SC-9420)
    • F.F.Taylor, W.W.Faloon The role of potassium in the natriuretic response to a steroidal lactone (SC-9420). J Clin Endocrinol Metab. 1959;19:1683–1687. doi:10.1210/jcem-19-12-1683.
    • (1959) J Clin Endocrinol Metab , vol.19 , pp. 1683-1687
    • Taylor, F.F.1    Faloon, W.W.2
  • 2
    • 84906807383 scopus 로고    scopus 로고
    • Four-membered ring-containing spirocycles: synthetic strategies and opportunities
    • E.M.Carreira, T.C.Fessard. Four-membered ring-containing spirocycles:synthetic strategies and opportunities. Chem Rev (Washington, DC, U S.). 2014;114:8257–8322. doi:10.1021/cr500127b.•• Important paper focused on four-membered spirocycles.
    • (2014) Chem Rev (Washington, DC, U S.) , vol.114 , pp. 8257-8322
    • Carreira, E.M.1    Fessard, T.C.2
  • 4
    • 10344242467 scopus 로고    scopus 로고
    • A library of spirooxindoles based on a stereoselective three-component coupling reaction
    • M.M.C.Lo, C.S.Neumann, S.Nagayama, et al. A library of spirooxindoles based on a stereoselective three-component coupling reaction. J Am Chem Soc. 2004;126:16077–16086. doi:10.1021/ja045089d.
    • (2004) J Am Chem Soc , vol.126 , pp. 16077-16086
    • Lo, M.M.C.1    Neumann, C.S.2    Nagayama, S.3
  • 5
    • 70350409235 scopus 로고    scopus 로고
    • The impact of aromatic ring count on compound developability: are too many aromatic rings a liability in drug design?
    • T.J.Ritchie, S.J.F.MacDonald. The impact of aromatic ring count on compound developability:are too many aromatic rings a liability in drug design? Drug Discov Today. 2009;14:1011–1020. doi:10.1016/j.drudis.2009.07.014.• Important article on the impact of aromatic ring count on developability.
    • (2009) Drug Discov Today , vol.14 , pp. 1011-1020
    • Ritchie, T.J.1    MacDonald, S.J.F.2
  • 6
    • 65649142070 scopus 로고    scopus 로고
    • Heteroaromatic rings of the future
    • W.R.Pitt, D.M.Parry, B.G.Perry, et al. Heteroaromatic rings of the future. J Med Chem. 2009;52:2952–2963. doi:10.1021/jm801513z.
    • (2009) J Med Chem , vol.52 , pp. 2952-2963
    • Pitt, W.R.1    Parry, D.M.2    Perry, B.G.3
  • 7
    • 84905924558 scopus 로고    scopus 로고
    • The use of spirocyclic scaffolds in drug discovery
    • Y.Zheng, C.M.Tice, S.B.Singh. The use of spirocyclic scaffolds in drug discovery. Bioorg Med Chem Lett. 2014;24:3673–3682. doi:10.1016/j.bmcl.2014.06.081.•• Review of recent spirocyclic scaffolds in drug discovery (2011–2014).
    • (2014) Bioorg Med Chem Lett , vol.24 , pp. 3673-3682
    • Zheng, Y.1    Tice, C.M.2    Singh, S.B.3
  • 8
    • 84879067500 scopus 로고    scopus 로고
    • Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer’s disease
    • J.Yuan, S.Venkatraman, Y.Zheng, et al. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer’s disease. J Med Chem. 2013;56:4156–4180. doi:10.1021/jm301659n.• Important review of SBDD for BACE1.
    • (2013) J Med Chem , vol.56 , pp. 4156-4180
    • Yuan, J.1    Venkatraman, S.2    Zheng, Y.3
  • 9
    • 84918559343 scopus 로고    scopus 로고
    • Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (AMG-8718)
    • T.A.Dineen, K.Chen, A.C.Cheng, et al. Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1):identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (AMG-8718). J Med Chem. 2014;57:9811–9831. doi:10.1021/jm5012676.
    • (2014) J Med Chem , vol.57 , pp. 9811-9831
    • Dineen, T.A.1    Chen, K.2    Cheng, A.C.3
  • 10
    • 84918513804 scopus 로고    scopus 로고
    • 8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors
    • A.A.Thomas, K.W.Hunt, B.Newhouse, et al. 8-Tetrahydropyran-2-yl chromans:highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors. J Med Chem. 2014;57:10112–10129. doi:10.1021/jm5015132.
    • (2014) J Med Chem , vol.57 , pp. 10112-10129
    • Thomas, A.A.1    Hunt, K.W.2    Newhouse, B.3
  • 11
    • 84982235705 scopus 로고    scopus 로고
    • Preparation of C-6 spirocarbocyclic iminothiadiazine dioxides as BACE inhibitors useful in treatment of diseases
    • Merck Sharp & Dohme Corp., USA. Preparation of C-6 spirocarbocyclic iminothiadiazine dioxides as BACE inhibitors useful in treatment of diseases. WO2015094930 (2015).
    • (2015) WO2015094930
  • 12
    • 84946550619 scopus 로고    scopus 로고
    • Fatty acid amide hydrolase inhibitors: a patent review (2009-2014)
    • A.Lodola, R.Castelli, M.Mor, et al. Fatty acid amide hydrolase inhibitors:a patent review (2009-2014). Expert Opin Ther Pat. 2015;25:1247–1266. doi:10.1517/13543776.2015.1067683.• Important review of fatty acid amide hydrolase inhibitor-related patents.
    • (2015) Expert Opin Ther Pat , vol.25 , pp. 1247-1266
    • Lodola, A.1    Castelli, R.2    Mor, M.3
  • 13
    • 80054791082 scopus 로고    scopus 로고
    • Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain
    • M.J.Meyers, S.A.Long, M.J.Pelc, et al. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain. Bioorg Med Chem Lett. 2011;21:6545–6553. doi:10.1016/j.bmcl.2011.08.048.
    • (2011) Bioorg Med Chem Lett , vol.21 , pp. 6545-6553
    • Meyers, M.J.1    Long, S.A.2    Pelc, M.J.3
  • 14
    • 84920165024 scopus 로고    scopus 로고
    • Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes
    • D.A.Griffith, D.W.Kung, W.P.Esler, et al. Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes. J Med Chem. 2014;57:10512–10526. doi:10.1021/jm5016022.
    • (2014) J Med Chem , vol.57 , pp. 10512-10526
    • Griffith, D.A.1    Kung, D.W.2    Esler, W.P.3
  • 15
    • 84939138677 scopus 로고    scopus 로고
    • Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones: benzisoxazole fusion with N-linked oxazolidinone substituents leading to a clinical candidate (ETX0914)
    • G.S.Basarab, P.Doig, V.Galullo, et al. Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones:benzisoxazole fusion with N-linked oxazolidinone substituents leading to a clinical candidate (ETX0914). J Med Chem. 2015;58:6264–6282. doi:10.1021/acs.jmedchem.5b00863.
    • (2015) J Med Chem , vol.58 , pp. 6264-6282
    • Basarab, G.S.1    Doig, P.2    Galullo, V.3
  • 16
    • 84955515384 scopus 로고    scopus 로고
    • Discovery of MK-8831, a novel spiro-proline macrocycle as a pan-genotypic HCV-NS3/4a protease inhibitor
    • S.F.Neelamkavil, S.Agrawal, T.Bara, et al. Discovery of MK-8831, a novel spiro-proline macrocycle as a pan-genotypic HCV-NS3/4a protease inhibitor. ACS Med Chem Lett. 2016;7:111–116. doi:10.1021/acsmedchemlett.5b00425.
    • (2016) ACS Med Chem Lett , vol.7 , pp. 111-116
    • Neelamkavil, S.F.1    Agrawal, S.2    Bara, T.3
  • 18
    • 0029129652 scopus 로고
    • Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue
    • A.A.Patchett, R.P.Nargund, J.R.Tata, et al. Design and biological activities of L-163,191 (MK-0677):a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995;92:7001–7005.
    • (1995) Proc Natl Acad Sci U S A , vol.92 , pp. 7001-7005
    • Patchett, A.A.1    Nargund, R.P.2    Tata, J.R.3
  • 19
    • 84982203121 scopus 로고    scopus 로고
    • Available from:, May
    • Phase 2 clinical trials of MK-1602. [cited 2016 May15]. Available from: https://clinicaltrials.gov/ct2/results?term=MK-1602&pg=1
    • Phase 2 clinical trials of MK-1602
  • 20
    • 84907794133 scopus 로고    scopus 로고
    • Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine
    • I.M.Bell. Calcitonin gene-related peptide receptor antagonists:new therapeutic agents for migraine. J Med Chem. 2014;57:7838–7858. doi:10.1021/jm500364u.
    • (2014) J Med Chem , vol.57 , pp. 7838-7858
    • Bell, I.M.1
  • 21
    • 84940613588 scopus 로고    scopus 로고
    • Role of rolapitant in chemotherapy-induced emesis
    • I.Olver. Role of rolapitant in chemotherapy-induced emesis. Lancet Oncol. 2015;16:1006–1007. doi:10.1016/S1470-2045(15)00096-0.
    • (2015) Lancet Oncol , vol.16 , pp. 1006-1007
    • Olver, I.1
  • 22
    • 79953732945 scopus 로고    scopus 로고
    • Molecular imaging of σ receptors: synthesis and evaluation of the potent σ1 selective radioligand [18F]fluspidine
    • S.Fischer, C.Wiese, E.Grosse Maestrup, et al. Molecular imaging of σ receptors:synthesis and evaluation of the potent σ1 selective radioligand [18F]fluspidine. Eur J Nucl Med Mol Imaging. 2011;38:540–551. doi:10.1007/s00259-010-1658-z.
    • (2011) Eur J Nucl Med Mol Imaging , vol.38 , pp. 540-551
    • Fischer, S.1    Wiese, C.2    Grosse Maestrup, E.3
  • 23
    • 84962185125 scopus 로고    scopus 로고
    • Discovery of (3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a melanin concentrating hormone receptor 1 (MCHr1) antagonist with favorable physicochemical properties
    • A.Johansson, C.Löfberg, M.Antonsson, et al. Discovery of (3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a melanin concentrating hormone receptor 1 (MCHr1) antagonist with favorable physicochemical properties. J Med Chem. 2016;59:2497–2511. doi:10.1021/acs.jmedchem.5b01797.
    • (2016) J Med Chem , vol.59 , pp. 2497-2511
    • Johansson, A.1    Löfberg, C.2    Antonsson, M.3
  • 24
    • 84896295869 scopus 로고    scopus 로고
    • Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection
    • J.O.Link, J.G.Taylor, L.Xu, et al. Discovery of ledipasvir (GS-5885):a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014;57:2033–2046. doi:10.1021/jm401499g.
    • (2014) J Med Chem , vol.57 , pp. 2033-2046
    • Link, J.O.1    Taylor, J.G.2    Xu, L.3
  • 25
    • 84896308812 scopus 로고    scopus 로고
    • Discovery and development of hepatitis C virus NS5A replication complex inhibitors
    • M.Belema, O.D.Lopez, J.A.Bender, et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J Med Chem. 2014;57:1643–1672. doi:10.1021/jm401793m.
    • (2014) J Med Chem , vol.57 , pp. 1643-1672
    • Belema, M.1    Lopez, O.D.2    Bender, J.A.3
  • 26
    • 84908148515 scopus 로고    scopus 로고
    • SAR405838: an optimized inhibitor of MDM2–p53 interaction that induces complete and durable tumor regression
    • S.Wang, W.Sun, Y.Zhao, et al. SAR405838:an optimized inhibitor of MDM2–p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014;74:5855–5865. doi:10.1158/0008-5472.CAN-14-0799.
    • (2014) Cancer Res , vol.74 , pp. 5855-5865
    • Wang, S.1    Sun, W.2    Zhao, Y.3
  • 27
    • 84866336965 scopus 로고    scopus 로고
    • Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
    • Y.Ohtake, T.Sato, T.Kobayashi, et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2012;55:7828–7840. doi:10.1021/jm300884k.
    • (2012) J Med Chem , vol.55 , pp. 7828-7840
    • Ohtake, Y.1    Sato, T.2    Kobayashi, T.3
  • 28
    • 84982235711 scopus 로고    scopus 로고
    • Boehringer Ingelheim International GmbH. Preparation of spirocyclic azoles and azines as inhibitors of β-secretase (BACE)
    • Vitae Pharmaceuticals, Inc., USA. Boehringer Ingelheim International GmbH. Preparation of spirocyclic azoles and azines as inhibitors of β-secretase (BACE). WO2010105179 (2010).
    • (2010) WO2010105179


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.